Pulse Biosciences announced on August 26, 2025, a new publication in the Journal Thyroid, detailing the first-in-human clinical feasibility study for the treatment of benign thyroid nodules using nsPFA energy. The study, conducted by Professor Stefano Spiezia, demonstrated the effectiveness of the CellFX nsPFA Percutaneous Electrode System.
Results showed that fully treated nodules in Cohort 3 achieved an average 86% reduction in size at one year, with some reaching up to 93% reduction, and significant symptom relief and over 48% reduction as early as two weeks. Crucially, follow-up ultrasounds revealed no intranodular fibrosis or scarring, highlighting a key safety advantage.
Dr. Ralph Tufano, Pulse Biosciences’ Scientific Advisory Board Chair, noted that nsPFA's non-thermal mechanism preserves surrounding nerves and blood vessels, allowing for safe treatment even near critical structures. He also highlighted nsPFA's significantly faster rate of thyroid nodule volume reduction, achieving 71% reduction within one month, compared to six months for comparable shrinkage with RFA-treated nodules in large clinical trials.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.